#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Addiction represents an enormous challenge to society .
1-1	0-9	Addiction	abstract	new	coref	5-16
1-2	10-20	represents	_	_	_	_
1-3	21-23	an	abstract[2]	new[2]	_	_
1-4	24-32	enormous	abstract[2]	new[2]	_	_
1-5	33-42	challenge	abstract[2]	new[2]	_	_
1-6	43-45	to	abstract[2]	new[2]	_	_
1-7	46-53	society	abstract[2]|abstract	new[2]|new	ana	2-3
1-8	54-55	.	_	_	_	_

#Text=Worldwide , it has been estimated that alcohol , tobacco , and illicit drugs were responsible for more than 10 million deaths , with a higher impact in developed countries where substance use disorders have been identified as responsible for life expectancy reversals .
2-1	56-65	Worldwide	place	new	_	_
2-2	66-67	,	_	_	_	_
2-3	68-70	it	abstract	giv	_	_
2-4	71-74	has	_	_	_	_
2-5	75-79	been	_	_	_	_
2-6	80-89	estimated	_	_	_	_
2-7	90-94	that	_	_	_	_
2-8	95-102	alcohol	substance	new	coref	17-55
2-9	103-104	,	_	_	_	_
2-10	105-112	tobacco	substance	new	_	_
2-11	113-114	,	_	_	_	_
2-12	115-118	and	_	_	_	_
2-13	119-126	illicit	substance[8]	new[8]	_	_
2-14	127-132	drugs	substance[8]	new[8]	_	_
2-15	133-137	were	_	_	_	_
2-16	138-149	responsible	_	_	_	_
2-17	150-153	for	_	_	_	_
2-18	154-158	more	event[9]	new[9]	_	_
2-19	159-163	than	event[9]	new[9]	_	_
2-20	164-166	10	event[9]	new[9]	_	_
2-21	167-174	million	event[9]	new[9]	_	_
2-22	175-181	deaths	event[9]	new[9]	_	_
2-23	182-183	,	_	_	_	_
2-24	184-188	with	_	_	_	_
2-25	189-190	a	abstract[10]	new[10]	_	_
2-26	191-197	higher	abstract[10]	new[10]	_	_
2-27	198-204	impact	abstract[10]	new[10]	_	_
2-28	205-207	in	abstract[10]	new[10]	_	_
2-29	208-217	developed	abstract[10]|place[11]	new[10]|new[11]	_	_
2-30	218-227	countries	abstract[10]|place[11]	new[10]|new[11]	_	_
2-31	228-233	where	_	_	_	_
2-32	234-243	substance	substance|abstract[14]	new|new[14]	coref	11-19
2-33	244-247	use	abstract|abstract[14]	new|new[14]	coref	11-20
2-34	248-257	disorders	abstract[14]	new[14]	_	_
2-35	258-262	have	_	_	_	_
2-36	263-267	been	_	_	_	_
2-37	268-278	identified	_	_	_	_
2-38	279-281	as	_	_	_	_
2-39	282-293	responsible	_	_	_	_
2-40	294-297	for	_	_	_	_
2-41	298-302	life	abstract|abstract[17]	new|new[17]	_	_
2-42	303-313	expectancy	abstract|abstract[17]	new|new[17]	_	_
2-43	314-323	reversals	abstract[17]	new[17]	_	_
2-44	324-325	.	_	_	_	_

#Text=Societal and medical responses to the problem are far from optimal , but the appearance of new technologies offers room for improvement , with lots of new initiatives launched and developed .
3-1	326-334	Societal	abstract[18]	new[18]	coref	11-35[108_18]
3-2	335-338	and	abstract[18]	new[18]	_	_
3-3	339-346	medical	abstract[18]	new[18]	_	_
3-4	347-356	responses	abstract[18]	new[18]	_	_
3-5	357-359	to	abstract[18]	new[18]	_	_
3-6	360-363	the	abstract[18]|abstract[19]	new[18]|new[19]	_	_
3-7	364-371	problem	abstract[18]|abstract[19]	new[18]|new[19]	_	_
3-8	372-375	are	_	_	_	_
3-9	376-379	far	_	_	_	_
3-10	380-384	from	_	_	_	_
3-11	385-392	optimal	_	_	_	_
3-12	393-394	,	_	_	_	_
3-13	395-398	but	_	_	_	_
3-14	399-402	the	abstract[20]	new[20]	_	_
3-15	403-413	appearance	abstract[20]	new[20]	_	_
3-16	414-416	of	abstract[20]	new[20]	_	_
3-17	417-420	new	abstract[20]|abstract[21]	new[20]|new[21]	coref	7-19[59_21]
3-18	421-433	technologies	abstract[20]|abstract[21]	new[20]|new[21]	_	_
3-19	434-440	offers	_	_	_	_
3-20	441-445	room	object	new	_	_
3-21	446-449	for	_	_	_	_
3-22	450-461	improvement	abstract	new	coref	5-28[45_0]
3-23	462-463	,	_	_	_	_
3-24	464-468	with	_	_	_	_
3-25	469-473	lots	abstract[24]	new[24]	_	_
3-26	474-476	of	abstract[24]	new[24]	_	_
3-27	477-480	new	abstract[24]	new[24]	_	_
3-28	481-492	initiatives	abstract[24]	new[24]	_	_
3-29	493-501	launched	_	_	_	_
3-30	502-505	and	_	_	_	_
3-31	506-515	developed	_	_	_	_
3-32	516-517	.	_	_	_	_

#Text=This special issue is intended to describe and discuss how these new tools are helping to improve the assessment and treatment of such old problems ( addictive disorders ) , covering a wide diversity of novelties that are being applied in the field .
4-1	518-522	This	abstract[25]	new[25]	coref	8-2[63_25]
4-2	523-530	special	abstract[25]	new[25]	_	_
4-3	531-536	issue	abstract[25]	new[25]	_	_
4-4	537-539	is	_	_	_	_
4-5	540-548	intended	_	_	_	_
4-6	549-551	to	_	_	_	_
4-7	552-560	describe	_	_	_	_
4-8	561-564	and	_	_	_	_
4-9	565-572	discuss	_	_	_	_
4-10	573-576	how	_	_	_	_
4-11	577-582	these	abstract[26]	new[26]	coref	21-8[192_26]
4-12	583-586	new	abstract[26]	new[26]	_	_
4-13	587-592	tools	abstract[26]	new[26]	_	_
4-14	593-596	are	_	_	_	_
4-15	597-604	helping	_	_	_	_
4-16	605-607	to	_	_	_	_
4-17	608-615	improve	_	_	_	_
4-18	616-619	the	abstract[27]	new[27]	coref	5-33[0_27]
4-19	620-630	assessment	abstract[27]	new[27]	_	_
4-20	631-634	and	_	_	_	_
4-21	635-644	treatment	abstract[28]	new[28]	coref	5-19[0_28]
4-22	645-647	of	abstract[28]	new[28]	_	_
4-23	648-652	such	abstract[28]|abstract[29]	new[28]|new[29]	appos	4-27[30_29]
4-24	653-656	old	abstract[28]|abstract[29]	new[28]|new[29]	_	_
4-25	657-665	problems	abstract[28]|abstract[29]	new[28]|new[29]	_	_
4-26	666-667	(	_	_	_	_
4-27	668-677	addictive	abstract[30]	giv[30]	coref	5-8[36_30]
4-28	678-687	disorders	abstract[30]	giv[30]	_	_
4-29	688-689	)	_	_	_	_
4-30	690-691	,	_	_	_	_
4-31	692-700	covering	_	_	_	_
4-32	701-702	a	abstract[31]	new[31]	_	_
4-33	703-707	wide	abstract[31]	new[31]	_	_
4-34	708-717	diversity	abstract[31]	new[31]	_	_
4-35	718-720	of	abstract[31]	new[31]	_	_
4-36	721-730	novelties	abstract[31]|abstract	new[31]|new	_	_
4-37	731-735	that	_	_	_	_
4-38	736-739	are	_	_	_	_
4-39	740-745	being	_	_	_	_
4-40	746-753	applied	_	_	_	_
4-41	754-756	in	_	_	_	_
4-42	757-760	the	abstract[33]	new[33]	coref	17-2[155_33]
4-43	761-766	field	abstract[33]	new[33]	_	_
4-44	767-768	.	_	_	_	_

#Text=Digital health entails the possibility to overcome existent problems around addictive disorders like stigmatization , addiction identification , treatment access , adherence and treatment efficacy by facilitating the improvement in knowledge , assessment , diagnosis , and treatment of addictive disorders .
5-1	769-776	Digital	abstract[34]	new[34]	coref	21-36[204_34]
5-2	777-783	health	abstract[34]	new[34]	_	_
5-3	784-791	entails	_	_	_	_
5-4	792-795	the	abstract[35]	new[35]	coref	10-6[88_35]
5-5	796-807	possibility	abstract[35]	new[35]	_	_
5-6	808-810	to	_	_	_	_
5-7	811-819	overcome	_	_	_	_
5-8	820-828	existent	abstract[36]	giv[36]	coref	5-40[50_36]
5-9	829-837	problems	abstract[36]	giv[36]	_	_
5-10	838-844	around	abstract[36]	giv[36]	_	_
5-11	845-854	addictive	abstract[36]	giv[36]	_	_
5-12	855-864	disorders	abstract[36]	giv[36]	_	_
5-13	865-869	like	abstract[36]	giv[36]	_	_
5-14	870-884	stigmatization	abstract[36]|abstract	giv[36]|new	_	_
5-15	885-886	,	abstract[36]	giv[36]	_	_
5-16	887-896	addiction	abstract[36]|abstract|abstract[39]	giv[36]|giv|new[39]	coref	9-21
5-17	897-911	identification	abstract[36]|abstract[39]	giv[36]|new[39]	_	_
5-18	912-913	,	abstract[36]	giv[36]	_	_
5-19	914-923	treatment	abstract[36]|abstract|abstract[41]	giv[36]|giv|new[41]	coref	5-24
5-20	924-930	access	abstract[36]|abstract[41]	giv[36]|new[41]	_	_
5-21	931-932	,	abstract[36]	giv[36]	_	_
5-22	933-942	adherence	abstract[36]|abstract	giv[36]|new	_	_
5-23	943-946	and	abstract[36]	giv[36]	_	_
5-24	947-956	treatment	abstract[36]|abstract|abstract[44]	giv[36]|giv|new[44]	_	_
5-25	957-965	efficacy	abstract[36]|abstract[44]	giv[36]|new[44]	_	_
5-26	966-968	by	_	_	_	_
5-27	969-981	facilitating	_	_	_	_
5-28	982-985	the	abstract[45]	giv[45]	_	_
5-29	986-997	improvement	abstract[45]	giv[45]	_	_
5-30	998-1000	in	abstract[45]	giv[45]	_	_
5-31	1001-1010	knowledge	abstract[45]|abstract	giv[45]|new	coref	11-27
5-32	1011-1012	,	abstract[45]	giv[45]	_	_
5-33	1013-1023	assessment	abstract[45]|abstract	giv[45]|giv	coref	6-1
5-34	1024-1025	,	abstract[45]	giv[45]	_	_
5-35	1026-1035	diagnosis	abstract[45]|event	giv[45]|new	coref	21-19
5-36	1036-1037	,	abstract[45]	giv[45]	_	_
5-37	1038-1041	and	abstract[45]	giv[45]	_	_
5-38	1042-1051	treatment	abstract[45]|abstract[49]	giv[45]|new[49]	coref	17-3[0_49]
5-39	1052-1054	of	abstract[45]|abstract[49]	giv[45]|new[49]	_	_
5-40	1055-1064	addictive	abstract[45]|abstract[49]|abstract[50]	giv[45]|new[49]|giv[50]	coref	11-19[105_50]
5-41	1065-1074	disorders	abstract[45]|abstract[49]|abstract[50]	giv[45]|new[49]|giv[50]	_	_
5-42	1075-1076	.	_	_	_	_

#Text=Assessment is one of the areas where new solutions have probably reached furthest .
6-1	1077-1087	Assessment	abstract	giv	coref	7-10[57_0]
6-2	1088-1090	is	_	_	_	_
6-3	1091-1094	one	abstract[52]	new[52]	_	_
6-4	1095-1097	of	abstract[52]	new[52]	_	_
6-5	1098-1101	the	abstract[52]|abstract[53]	new[52]|new[53]	_	_
6-6	1102-1107	areas	abstract[52]|abstract[53]	new[52]|new[53]	_	_
6-7	1108-1113	where	_	_	_	_
6-8	1114-1117	new	abstract[54]	new[54]	coref	15-11[139_54]
6-9	1118-1127	solutions	abstract[54]	new[54]	_	_
6-10	1128-1132	have	_	_	_	_
6-11	1133-1141	probably	_	_	_	_
6-12	1142-1149	reached	_	_	_	_
6-13	1150-1158	furthest	_	_	_	_
6-14	1159-1160	.	_	_	_	_

#Text=Think , for example , about transdermal sensors and ecological momentary assessment : a clear example of how new technologies can reach the core of a patient ’s drinking pattern .
7-1	1161-1166	Think	_	_	_	_
7-2	1167-1168	,	_	_	_	_
7-3	1169-1172	for	_	_	_	_
7-4	1173-1180	example	_	_	_	_
7-5	1181-1182	,	_	_	_	_
7-6	1183-1188	about	_	_	_	_
7-7	1189-1200	transdermal	object|object[56]	new|new[56]	coref|coref	8-14|8-14[67_56]
7-8	1201-1208	sensors	object[56]	new[56]	_	_
7-9	1209-1212	and	_	_	_	_
7-10	1213-1223	ecological	abstract[57]	giv[57]	coref	10-44[95_57]
7-11	1224-1233	momentary	abstract[57]	giv[57]	_	_
7-12	1234-1244	assessment	abstract[57]	giv[57]	_	_
7-13	1245-1246	:	_	_	_	_
7-14	1247-1248	a	abstract[58]	new[58]	_	_
7-15	1249-1254	clear	abstract[58]	new[58]	_	_
7-16	1255-1262	example	abstract[58]	new[58]	_	_
7-17	1263-1265	of	abstract[58]	new[58]	_	_
7-18	1266-1269	how	abstract[58]	new[58]	_	_
7-19	1270-1273	new	abstract[59]	giv[59]	coref	9-1[69_59]
7-20	1274-1286	technologies	abstract[59]	giv[59]	_	_
7-21	1287-1290	can	_	_	_	_
7-22	1291-1296	reach	_	_	_	_
7-23	1297-1300	the	abstract[60]	new[60]	_	_
7-24	1301-1305	core	abstract[60]	new[60]	_	_
7-25	1306-1308	of	abstract[60]	new[60]	_	_
7-26	1309-1310	a	abstract[60]|abstract[62]	new[60]|new[62]	_	_
7-27	1311-1318	patient	abstract[60]|person[61]|abstract[62]	new[60]|new[61]|new[62]	_	_
7-28	1319-1321	’s	abstract[60]|person[61]|abstract[62]	new[60]|new[61]|new[62]	_	_
7-29	1322-1330	drinking	abstract[60]|abstract[62]	new[60]|new[62]	_	_
7-30	1331-1338	pattern	abstract[60]|abstract[62]	new[60]|new[62]	_	_
7-31	1339-1340	.	_	_	_	_

#Text=In this special issue , Barrio et al. investigate patients ’ attitudes towards transdermal sensors in real clinical settings .
8-1	1341-1343	In	_	_	_	_
8-2	1344-1348	this	abstract[63]	giv[63]	coref	17-6[156_63]
8-3	1349-1356	special	abstract[63]	giv[63]	_	_
8-4	1357-1362	issue	abstract[63]	giv[63]	_	_
8-5	1363-1364	,	_	_	_	_
8-6	1365-1371	Barrio	_	_	_	_
8-7	1372-1374	et	_	_	_	_
8-8	1375-1378	al.	_	_	_	_
8-9	1379-1390	investigate	_	_	_	_
8-10	1391-1399	patients	person[64]|abstract[65]	new[64]|new[65]	ana	9-12[0_64]
8-11	1400-1401	’	person[64]|abstract[65]	new[64]|new[65]	_	_
8-12	1402-1411	attitudes	abstract[65]	new[65]	_	_
8-13	1412-1419	towards	abstract[65]	new[65]	_	_
8-14	1420-1431	transdermal	abstract[65]|object|object[67]	new[65]|giv|giv[67]	_	_
8-15	1432-1439	sensors	abstract[65]|object[67]	new[65]|giv[67]	_	_
8-16	1440-1442	in	abstract[65]|object[67]	new[65]|giv[67]	_	_
8-17	1443-1447	real	abstract[65]|object[67]|place[68]	new[65]|giv[67]|new[68]	_	_
8-18	1448-1456	clinical	abstract[65]|object[67]|place[68]	new[65]|giv[67]|new[68]	_	_
8-19	1457-1465	settings	abstract[65]|object[67]|place[68]	new[65]|giv[67]|new[68]	_	_
8-20	1466-1467	.	_	_	_	_

#Text=Digital technologies might be useful to assess brain damage , and they bring us closer to understanding the mechanism(s) underlying addiction . Herreros et al. present a visuomotor rotation task which might be the first step towards developing a useful tool for the detection of cerebellum dysfunction by assessing alterations in implicit learning among chronic cannabis users .
9-1	1468-1475	Digital	abstract[69]	giv[69]	coref	10-1[87_69]
9-2	1476-1488	technologies	abstract[69]	giv[69]	_	_
9-3	1489-1494	might	_	_	_	_
9-4	1495-1497	be	_	_	_	_
9-5	1498-1504	useful	_	_	_	_
9-6	1505-1507	to	_	_	_	_
9-7	1508-1514	assess	_	_	_	_
9-8	1515-1520	brain	object|abstract[71]	new|new[71]	_	_
9-9	1521-1527	damage	abstract[71]	new[71]	_	_
9-10	1528-1529	,	_	_	_	_
9-11	1530-1533	and	_	_	_	_
9-12	1534-1538	they	person	giv	coref	10-12
9-13	1539-1544	bring	_	_	_	_
9-14	1545-1547	us	person	acc	ana	10-28
9-15	1548-1554	closer	_	_	_	_
9-16	1555-1557	to	_	_	_	_
9-17	1558-1571	understanding	_	_	_	_
9-18	1572-1575	the	abstract[74]	new[74]	_	_
9-19	1576-1588	mechanism(s)	abstract[74]	new[74]	_	_
9-20	1589-1599	underlying	_	_	_	_
9-21	1600-1609	addiction	event	giv	coref	12-23[117_0]
9-22	1610-1611	.	_	_	_	_
9-23	1612-1620	Herreros	person	new	_	_
9-24	1621-1623	et	_	_	_	_
9-25	1624-1627	al.	_	_	_	_
9-26	1628-1635	present	_	_	_	_
9-27	1636-1637	a	abstract[78]	new[78]	_	_
9-28	1638-1648	visuomotor	abstract[78]	new[78]	_	_
9-29	1649-1657	rotation	abstract|abstract[78]	new|new[78]	_	_
9-30	1658-1662	task	abstract[78]	new[78]	_	_
9-31	1663-1668	which	_	_	_	_
9-32	1669-1674	might	_	_	_	_
9-33	1675-1677	be	_	_	_	_
9-34	1678-1681	the	abstract[79]	new[79]	_	_
9-35	1682-1687	first	abstract[79]	new[79]	_	_
9-36	1688-1692	step	abstract[79]	new[79]	_	_
9-37	1693-1700	towards	_	_	_	_
9-38	1701-1711	developing	_	_	_	_
9-39	1712-1713	a	abstract[80]	new[80]	_	_
9-40	1714-1720	useful	abstract[80]	new[80]	_	_
9-41	1721-1725	tool	abstract[80]	new[80]	_	_
9-42	1726-1729	for	abstract[80]	new[80]	_	_
9-43	1730-1733	the	abstract[80]|abstract[81]	new[80]|new[81]	_	_
9-44	1734-1743	detection	abstract[80]|abstract[81]	new[80]|new[81]	_	_
9-45	1744-1746	of	abstract[80]|abstract[81]	new[80]|new[81]	_	_
9-46	1747-1757	cerebellum	abstract[80]|abstract[81]|abstract[82]	new[80]|new[81]|new[82]	_	_
9-47	1758-1769	dysfunction	abstract[80]|abstract[81]|abstract[82]	new[80]|new[81]|new[82]	_	_
9-48	1770-1772	by	_	_	_	_
9-49	1773-1782	assessing	_	_	_	_
9-50	1783-1794	alterations	abstract[83]	new[83]	_	_
9-51	1795-1797	in	abstract[83]	new[83]	_	_
9-52	1798-1806	implicit	abstract[83]|abstract[84]	new[83]|new[84]	coref	12-19[0_84]
9-53	1807-1815	learning	abstract[83]|abstract[84]	new[83]|new[84]	_	_
9-54	1816-1821	among	abstract[83]|abstract[84]	new[83]|new[84]	_	_
9-55	1822-1829	chronic	abstract[83]|abstract[84]|person[86]	new[83]|new[84]|new[86]	_	_
9-56	1830-1838	cannabis	abstract[83]|abstract[84]|substance|person[86]	new[83]|new[84]|new|new[86]	coref	20-28
9-57	1839-1844	users	abstract[83]|abstract[84]|person[86]	new[83]|new[84]|new[86]	_	_
9-58	1845-1846	.	_	_	_	_

#Text=New technologies have opened up the possibility of not only assessing patients “ right here right now ” but also of creating new realities , or should we better say virtual realities ? Ghiţă et al. show us that virtual reality can enhance the assessment of alcohol-induced craving and anxiety .
10-1	1847-1850	New	abstract[87]	giv[87]	coref	13-4[124_87]
10-2	1851-1863	technologies	abstract[87]	giv[87]	_	_
10-3	1864-1868	have	_	_	_	_
10-4	1869-1875	opened	_	_	_	_
10-5	1876-1878	up	_	_	_	_
10-6	1879-1882	the	abstract[88]	giv[88]	_	_
10-7	1883-1894	possibility	abstract[88]	giv[88]	_	_
10-8	1895-1897	of	_	_	_	_
10-9	1898-1901	not	_	_	_	_
10-10	1902-1906	only	_	_	_	_
10-11	1907-1916	assessing	_	_	_	_
10-12	1917-1925	patients	person	giv	ana	16-1
10-13	1926-1927	“	_	_	_	_
10-14	1928-1933	right	_	_	_	_
10-15	1934-1938	here	_	_	_	_
10-16	1939-1944	right	_	_	_	_
10-17	1945-1948	now	_	_	_	_
10-18	1949-1950	”	_	_	_	_
10-19	1951-1954	but	_	_	_	_
10-20	1955-1959	also	_	_	_	_
10-21	1960-1962	of	_	_	_	_
10-22	1963-1971	creating	_	_	_	_
10-23	1972-1975	new	abstract[90]	new[90]	coref	10-31[92_90]
10-24	1976-1985	realities	abstract[90]	new[90]	_	_
10-25	1986-1987	,	_	_	_	_
10-26	1988-1990	or	_	_	_	_
10-27	1991-1997	should	_	_	_	_
10-28	1998-2000	we	person	giv	ana	10-38
10-29	2001-2007	better	_	_	_	_
10-30	2008-2011	say	_	_	_	_
10-31	2012-2019	virtual	abstract[92]	giv[92]	_	_
10-32	2020-2029	realities	abstract[92]	giv[92]	_	_
10-33	2030-2031	?	_	_	_	_
10-34	2032-2037	Ghiţă	_	_	_	_
10-35	2038-2040	et	_	_	_	_
10-36	2041-2044	al.	_	_	_	_
10-37	2045-2049	show	_	_	_	_
10-38	2050-2052	us	person	giv	ana	16-3
10-39	2053-2057	that	_	_	_	_
10-40	2058-2065	virtual	object[94]	new[94]	_	_
10-41	2066-2073	reality	object[94]	new[94]	_	_
10-42	2074-2077	can	_	_	_	_
10-43	2078-2085	enhance	_	_	_	_
10-44	2086-2089	the	abstract[95]	giv[95]	coref	14-19[0_95]
10-45	2090-2100	assessment	abstract[95]	giv[95]	_	_
10-46	2101-2103	of	abstract[95]	giv[95]	_	_
10-47	2104-2119	alcohol-induced	abstract[95]|abstract[96]	giv[95]|new[96]	_	_
10-48	2120-2127	craving	abstract[95]|abstract[96]	giv[95]|new[96]	_	_
10-49	2128-2131	and	abstract[95]	giv[95]	_	_
10-50	2132-2139	anxiety	abstract[95]|abstract	giv[95]|new	_	_
10-51	2140-2141	.	_	_	_	_

#Text=Technological advances in neuroimaging and genetics have allowed deepening in the understanding of some learning processes involved in substance use disorders . Garbusow et al. provide knowledge on how important processes , such as instrumental responses to relevant stimuli , are influenced by drinking patterns .
11-1	2142-2155	Technological	abstract[98]	new[98]	coref	21-1[190_98]
11-2	2156-2164	advances	abstract[98]	new[98]	_	_
11-3	2165-2167	in	abstract[98]	new[98]	_	_
11-4	2168-2180	neuroimaging	abstract[98]|abstract	new[98]|new	_	_
11-5	2181-2184	and	abstract[98]	new[98]	_	_
11-6	2185-2193	genetics	abstract[98]|abstract	new[98]|new	_	_
11-7	2194-2198	have	_	_	_	_
11-8	2199-2206	allowed	_	_	_	_
11-9	2207-2216	deepening	_	_	_	_
11-10	2217-2219	in	_	_	_	_
11-11	2220-2223	the	abstract[101]	new[101]	_	_
11-12	2224-2237	understanding	abstract[101]	new[101]	_	_
11-13	2238-2240	of	abstract[101]	new[101]	_	_
11-14	2241-2245	some	abstract[101]|abstract[102]	new[101]|new[102]	coref	11-30[107_102]
11-15	2246-2254	learning	abstract[101]|abstract[102]	new[101]|new[102]	_	_
11-16	2255-2264	processes	abstract[101]|abstract[102]	new[101]|new[102]	_	_
11-17	2265-2273	involved	_	_	_	_
11-18	2274-2276	in	_	_	_	_
11-19	2277-2286	substance	substance|abstract[105]	giv|giv[105]	coref	15-14[140_105]
11-20	2287-2290	use	abstract|abstract[105]	giv|giv[105]	coref	18-1[174_0]
11-21	2291-2300	disorders	abstract[105]	giv[105]	_	_
11-22	2301-2302	.	_	_	_	_
11-23	2303-2311	Garbusow	_	_	_	_
11-24	2312-2314	et	_	_	_	_
11-25	2315-2318	al.	_	_	_	_
11-26	2319-2326	provide	_	_	_	_
11-27	2327-2336	knowledge	abstract	giv	coref	21-14[195_0]
11-28	2337-2339	on	_	_	_	_
11-29	2340-2343	how	_	_	_	_
11-30	2344-2353	important	abstract[107]	giv[107]	_	_
11-31	2354-2363	processes	abstract[107]	giv[107]	_	_
11-32	2364-2365	,	abstract[107]	giv[107]	_	_
11-33	2366-2370	such	abstract[107]	giv[107]	_	_
11-34	2371-2373	as	abstract[107]	giv[107]	_	_
11-35	2374-2386	instrumental	abstract[107]|abstract[108]	giv[107]|giv[108]	_	_
11-36	2387-2396	responses	abstract[107]|abstract[108]	giv[107]|giv[108]	_	_
11-37	2397-2399	to	abstract[107]|abstract[108]	giv[107]|giv[108]	_	_
11-38	2400-2408	relevant	abstract[107]|abstract[108]|abstract[109]	giv[107]|giv[108]|new[109]	_	_
11-39	2409-2416	stimuli	abstract[107]|abstract[108]|abstract[109]	giv[107]|giv[108]|new[109]	_	_
11-40	2417-2418	,	_	_	_	_
11-41	2419-2422	are	_	_	_	_
11-42	2423-2433	influenced	_	_	_	_
11-43	2434-2436	by	_	_	_	_
11-44	2437-2445	drinking	_	_	_	_
11-45	2446-2454	patterns	abstract	new	_	_
11-46	2455-2456	.	_	_	_	_

#Text=In this same line , Heinz et al. conduct a review that starts with how Pavlovian and instrumental learning mechanisms interact in drug addiction and finishes with how these learning mechanisms and their respective neurobiological correlates can contribute to losing versus regaining control over drug intake .
12-1	2457-2459	In	_	_	_	_
12-2	2460-2464	this	abstract[111]	new[111]	_	_
12-3	2465-2469	same	abstract[111]	new[111]	_	_
12-4	2470-2474	line	abstract[111]	new[111]	_	_
12-5	2475-2476	,	_	_	_	_
12-6	2477-2482	Heinz	person	new	_	_
12-7	2483-2485	et	_	_	_	_
12-8	2486-2489	al.	_	_	_	_
12-9	2490-2497	conduct	_	_	_	_
12-10	2498-2499	a	abstract[113]	new[113]	_	_
12-11	2500-2506	review	abstract[113]	new[113]	_	_
12-12	2507-2511	that	_	_	_	_
12-13	2512-2518	starts	_	_	_	_
12-14	2519-2523	with	_	_	_	_
12-15	2524-2527	how	_	_	_	_
12-16	2528-2537	Pavlovian	abstract[115]	new[115]	coref	12-29[119_115]
12-17	2538-2541	and	abstract[115]	new[115]	_	_
12-18	2542-2554	instrumental	abstract[115]	new[115]	_	_
12-19	2555-2563	learning	abstract|abstract[115]	giv|new[115]	coref	12-30
12-20	2564-2574	mechanisms	abstract[115]	new[115]	_	_
12-21	2575-2583	interact	_	_	_	_
12-22	2584-2586	in	_	_	_	_
12-23	2587-2591	drug	substance|event[117]	new|giv[117]	coref|coref	12-45|14-22[134_117]
12-24	2592-2601	addiction	event[117]	giv[117]	_	_
12-25	2602-2605	and	_	_	_	_
12-26	2606-2614	finishes	_	_	_	_
12-27	2615-2619	with	_	_	_	_
12-28	2620-2623	how	_	_	_	_
12-29	2624-2629	these	abstract[119]	giv[119]	_	_
12-30	2630-2638	learning	abstract|abstract[119]	giv|giv[119]	_	_
12-31	2639-2649	mechanisms	abstract[119]	giv[119]	_	_
12-32	2650-2653	and	abstract[119]	giv[119]	_	_
12-33	2654-2659	their	abstract[119]|abstract[120]	giv[119]|new[120]	_	_
12-34	2660-2670	respective	abstract[119]|abstract[120]	giv[119]|new[120]	_	_
12-35	2671-2686	neurobiological	abstract[119]|abstract[120]	giv[119]|new[120]	_	_
12-36	2687-2697	correlates	abstract[119]|abstract[120]	giv[119]|new[120]	_	_
12-37	2698-2701	can	_	_	_	_
12-38	2702-2712	contribute	_	_	_	_
12-39	2713-2715	to	_	_	_	_
12-40	2716-2722	losing	_	_	_	_
12-41	2723-2729	versus	_	_	_	_
12-42	2730-2739	regaining	_	_	_	_
12-43	2740-2747	control	abstract	new	_	_
12-44	2748-2752	over	_	_	_	_
12-45	2753-2757	drug	substance|abstract[123]	giv|new[123]	_	_
12-46	2758-2764	intake	abstract[123]	new[123]	_	_
12-47	2765-2766	.	_	_	_	_

#Text=Paradoxically enough , new technologies do also have their own risks .
13-1	2767-2780	Paradoxically	_	_	_	_
13-2	2781-2787	enough	_	_	_	_
13-3	2788-2789	,	_	_	_	_
13-4	2790-2793	new	abstract[124]	giv[124]	ana	13-9[0_124]
13-5	2794-2806	technologies	abstract[124]	giv[124]	_	_
13-6	2807-2809	do	_	_	_	_
13-7	2810-2814	also	_	_	_	_
13-8	2815-2819	have	_	_	_	_
13-9	2820-2825	their	abstract|abstract[126]	giv|new[126]	coref	21-4[191_0]
13-10	2826-2829	own	abstract[126]	new[126]	_	_
13-11	2830-2835	risks	abstract[126]	new[126]	_	_
13-12	2836-2837	.	_	_	_	_

#Text=Take , for example , internet gaming disorder . Ryu et al. present the development of a new assessment instrument for internet addiction , the Diagnostic Interview for Internet Addiction .
14-1	2838-2842	Take	_	_	_	_
14-2	2843-2844	,	_	_	_	_
14-3	2845-2848	for	_	_	_	_
14-4	2849-2856	example	_	_	_	_
14-5	2857-2858	,	_	_	_	_
14-6	2859-2867	internet	place|abstract[129]	new|new[129]	coref	14-22
14-7	2868-2874	gaming	abstract|abstract[129]	new|new[129]	_	_
14-8	2875-2883	disorder	abstract[129]	new[129]	_	_
14-9	2884-2885	.	_	_	_	_
14-10	2886-2889	Ryu	_	_	_	_
14-11	2890-2892	et	_	_	_	_
14-12	2893-2896	al.	_	_	_	_
14-13	2897-2904	present	_	_	_	_
14-14	2905-2908	the	abstract[130]	new[130]	_	_
14-15	2909-2920	development	abstract[130]	new[130]	_	_
14-16	2921-2923	of	abstract[130]	new[130]	_	_
14-17	2924-2925	a	abstract[130]|abstract[132]	new[130]|new[132]	_	_
14-18	2926-2929	new	abstract[130]|abstract[132]	new[130]|new[132]	_	_
14-19	2930-2940	assessment	abstract[130]|abstract|abstract[132]	new[130]|giv|new[132]	_	_
14-20	2941-2951	instrument	abstract[130]|abstract[132]	new[130]|new[132]	_	_
14-21	2952-2955	for	abstract[130]|abstract[132]	new[130]|new[132]	_	_
14-22	2956-2964	internet	abstract[130]|abstract[132]|place|event[134]	new[130]|new[132]|giv|giv[134]	coref	14-29[137_134]
14-23	2965-2974	addiction	abstract[130]|abstract[132]|event[134]	new[130]|new[132]|giv[134]	_	_
14-24	2975-2976	,	_	_	_	_
14-25	2977-2980	the	object[136]	new[136]	_	_
14-26	2981-2991	Diagnostic	abstract|object[136]	new|new[136]	_	_
14-27	2992-3001	Interview	object[136]	new[136]	_	_
14-28	3002-3005	for	object[136]	new[136]	_	_
14-29	3006-3014	Internet	object[136]|abstract[137]	new[136]|giv[137]	coref	15-25[0_137]
14-30	3015-3024	Addiction	object[136]|abstract[137]	new[136]|giv[137]	_	_
14-31	3025-3026	.	_	_	_	_

#Text=And keeping in mind that new psychometric instruments are also new solutions to old problems , Chen et al. investigate an interesting phenomenon in addiction : the intensity of memory addiction .
15-1	3027-3030	And	_	_	_	_
15-2	3031-3038	keeping	_	_	_	_
15-3	3039-3041	in	_	_	_	_
15-4	3042-3046	mind	_	_	_	_
15-5	3047-3051	that	_	_	_	_
15-6	3052-3055	new	abstract[138]	new[138]	_	_
15-7	3056-3068	psychometric	abstract[138]	new[138]	_	_
15-8	3069-3080	instruments	abstract[138]	new[138]	_	_
15-9	3081-3084	are	_	_	_	_
15-10	3085-3089	also	_	_	_	_
15-11	3090-3093	new	abstract[139]	giv[139]	_	_
15-12	3094-3103	solutions	abstract[139]	giv[139]	_	_
15-13	3104-3106	to	abstract[139]	giv[139]	_	_
15-14	3107-3110	old	abstract[139]|abstract[140]	giv[139]|giv[140]	coref	20-13[185_140]
15-15	3111-3119	problems	abstract[139]|abstract[140]	giv[139]|giv[140]	_	_
15-16	3120-3121	,	abstract[139]	giv[139]	_	_
15-17	3122-3126	Chen	abstract[139]|person	giv[139]|new	_	_
15-18	3127-3129	et	abstract[139]	giv[139]	_	_
15-19	3130-3133	al.	abstract[139]	giv[139]	_	_
15-20	3134-3145	investigate	_	_	_	_
15-21	3146-3148	an	abstract[142]	new[142]	_	_
15-22	3149-3160	interesting	abstract[142]	new[142]	_	_
15-23	3161-3171	phenomenon	abstract[142]	new[142]	_	_
15-24	3172-3174	in	abstract[142]	new[142]	_	_
15-25	3175-3184	addiction	abstract[142]|event	new[142]|giv	coref	15-30[146_0]
15-26	3185-3186	:	_	_	_	_
15-27	3187-3190	the	abstract[144]	new[144]	coref	16-10[0_144]
15-28	3191-3200	intensity	abstract[144]	new[144]	_	_
15-29	3201-3203	of	abstract[144]	new[144]	_	_
15-30	3204-3210	memory	abstract[144]|abstract|event[146]	new[144]|new|giv[146]	coref|coref	16-8[0_146]|16-8[151_0]
15-31	3211-3220	addiction	abstract[144]|event[146]	new[144]|giv[146]	_	_
15-32	3221-3222	.	_	_	_	_

#Text=They present us the development of the Addiction Memory Intensity Scale .
16-1	3223-3227	They	person	giv	coref	18-17[179_0]
16-2	3228-3235	present	_	_	_	_
16-3	3236-3238	us	person	giv	ana	21-12
16-4	3239-3242	the	abstract[149]	new[149]	_	_
16-5	3243-3254	development	abstract[149]	new[149]	_	_
16-6	3255-3257	of	abstract[149]	new[149]	_	_
16-7	3258-3261	the	abstract[149]|abstract[153]	new[149]|new[153]	_	_
16-8	3262-3271	Addiction	abstract[149]|abstract|abstract[151]|abstract[153]	new[149]|giv|giv[151]|new[153]	coref	20-28[189_0]
16-9	3272-3278	Memory	abstract[149]|abstract[151]|abstract[153]	new[149]|giv[151]|new[153]	_	_
16-10	3279-3288	Intensity	abstract[149]|abstract|abstract[153]	new[149]|giv|new[153]	_	_
16-11	3289-3294	Scale	abstract[149]|abstract[153]	new[149]|new[153]	_	_
16-12	3295-3296	.	_	_	_	_

#Text=In the treatment area , this special issue offers an interesting combination of modalities : newly designed pharmaceutical compounds ( nalmefene ) , naturally occurring psychoactive substances ( cannabidiol ) , and non-pharmacological , biological therapies ( rTMS ) . Barrio et al. report the main effectiveness analysis of a phase-IV study conducted among alcohol dependent outpatients taking nalmefene , the only approved medication for alcohol reduction aims .
17-1	3297-3299	In	_	_	_	_
17-2	3300-3303	the	abstract[155]	giv[155]	_	_
17-3	3304-3313	treatment	abstract|abstract[155]	giv|giv[155]	_	_
17-4	3314-3318	area	abstract[155]	giv[155]	_	_
17-5	3319-3320	,	_	_	_	_
17-6	3321-3325	this	abstract[156]	giv[156]	_	_
17-7	3326-3333	special	abstract[156]	giv[156]	_	_
17-8	3334-3339	issue	abstract[156]	giv[156]	_	_
17-9	3340-3346	offers	_	_	_	_
17-10	3347-3349	an	abstract[157]	new[157]	_	_
17-11	3350-3361	interesting	abstract[157]	new[157]	_	_
17-12	3362-3373	combination	abstract[157]	new[157]	_	_
17-13	3374-3376	of	abstract[157]	new[157]	_	_
17-14	3377-3387	modalities	abstract[157]|abstract	new[157]|new	_	_
17-15	3388-3389	:	_	_	_	_
17-16	3390-3395	newly	_	_	_	_
17-17	3396-3404	designed	_	_	_	_
17-18	3405-3419	pharmaceutical	_	_	_	_
17-19	3420-3429	compounds	_	_	_	_
17-20	3430-3431	(	_	_	_	_
17-21	3432-3441	nalmefene	substance	new	coref	17-59
17-22	3442-3443	)	_	_	_	_
17-23	3444-3445	,	_	_	_	_
17-24	3446-3455	naturally	_	_	_	_
17-25	3456-3465	occurring	_	_	_	_
17-26	3466-3478	psychoactive	substance[160]	new[160]	appos	17-29[0_160]
17-27	3479-3489	substances	substance[160]	new[160]	_	_
17-28	3490-3491	(	_	_	_	_
17-29	3492-3503	cannabidiol	substance	giv	_	_
17-30	3504-3505	)	_	_	_	_
17-31	3506-3507	,	_	_	_	_
17-32	3508-3511	and	_	_	_	_
17-33	3512-3531	non-pharmacological	abstract[162]	new[162]	appos	17-38[0_162]
17-34	3532-3533	,	abstract[162]	new[162]	_	_
17-35	3534-3544	biological	abstract[162]	new[162]	_	_
17-36	3545-3554	therapies	abstract[162]	new[162]	_	_
17-37	3555-3556	(	_	_	_	_
17-38	3557-3561	rTMS	abstract	giv	coref	18-4
17-39	3562-3563	)	_	_	_	_
17-40	3564-3565	.	_	_	_	_
17-41	3566-3572	Barrio	_	_	_	_
17-42	3573-3575	et	_	_	_	_
17-43	3576-3579	al.	_	_	_	_
17-44	3580-3586	report	abstract[165]	new[165]	_	_
17-45	3587-3590	the	abstract[165]	new[165]	_	_
17-46	3591-3595	main	abstract[165]	new[165]	_	_
17-47	3596-3609	effectiveness	abstract|abstract[165]	new|new[165]	_	_
17-48	3610-3618	analysis	abstract[165]	new[165]	_	_
17-49	3619-3621	of	abstract[165]	new[165]	_	_
17-50	3622-3623	a	abstract[165]|abstract[166]	new[165]|new[166]	_	_
17-51	3624-3632	phase-IV	abstract[165]|abstract[166]	new[165]|new[166]	_	_
17-52	3633-3638	study	abstract[165]|abstract[166]	new[165]|new[166]	_	_
17-53	3639-3648	conducted	abstract[165]	new[165]	_	_
17-54	3649-3654	among	abstract[165]	new[165]	_	_
17-55	3655-3662	alcohol	abstract[165]|substance	new[165]|giv	coref	17-66
17-56	3663-3672	dependent	abstract[165]|person[168]	new[165]|new[168]	_	_
17-57	3673-3684	outpatients	abstract[165]|person[168]	new[165]|new[168]	_	_
17-58	3685-3691	taking	abstract[165]	new[165]	_	_
17-59	3692-3701	nalmefene	abstract[165]|substance	new[165]|giv	_	_
17-60	3702-3703	,	abstract[165]	new[165]	_	_
17-61	3704-3707	the	abstract[165]|substance[170]	new[165]|new[170]	_	_
17-62	3708-3712	only	abstract[165]|substance[170]	new[165]|new[170]	_	_
17-63	3713-3721	approved	abstract[165]|substance[170]	new[165]|new[170]	_	_
17-64	3722-3732	medication	abstract[165]|substance[170]	new[165]|new[170]	_	_
17-65	3733-3736	for	abstract[165]|substance[170]	new[165]|new[170]	_	_
17-66	3737-3744	alcohol	abstract[165]|substance[170]|substance|abstract[173]	new[165]|new[170]|giv|new[173]	_	_
17-67	3745-3754	reduction	abstract[165]|substance[170]|abstract|abstract[173]	new[165]|new[170]|new|new[173]	_	_
17-68	3755-3759	aims	abstract[165]|substance[170]|abstract[173]	new[165]|new[170]|new[173]	_	_
17-69	3760-3761	.	_	_	_	_

#Text=The use of rTMS is presented by Cardullo et al. in a sample of cocaine and gambling patients .
18-1	3762-3765	The	abstract[174]	giv[174]	_	_
18-2	3766-3769	use	abstract[174]	giv[174]	_	_
18-3	3770-3772	of	abstract[174]	giv[174]	_	_
18-4	3773-3777	rTMS	abstract[174]|abstract	giv[174]|giv	_	_
18-5	3778-3780	is	_	_	_	_
18-6	3781-3790	presented	_	_	_	_
18-7	3791-3793	by	_	_	_	_
18-8	3794-3802	Cardullo	_	_	_	_
18-9	3803-3805	et	_	_	_	_
18-10	3806-3809	al.	_	_	_	_
18-11	3810-3812	in	_	_	_	_
18-12	3813-3814	a	person[176]	new[176]	_	_
18-13	3815-3821	sample	person[176]	new[176]	_	_
18-14	3822-3824	of	person[176]	new[176]	_	_
18-15	3825-3832	cocaine	person[176]|substance	new[176]|new	_	_
18-16	3833-3836	and	person[176]	new[176]	_	_
18-17	3837-3845	gambling	person[176]|abstract|person[179]	new[176]|new|giv[179]	_	_
18-18	3846-3854	patients	person[176]|person[179]	new[176]|giv[179]	_	_
18-19	3855-3856	.	_	_	_	_

#Text=The stimulation of the left dorsolateral prefrontal cortex yields promising results .
19-1	3857-3860	The	abstract[180]	new[180]	_	_
19-2	3861-3872	stimulation	abstract[180]	new[180]	_	_
19-3	3873-3875	of	abstract[180]	new[180]	_	_
19-4	3876-3879	the	abstract[180]|place[181]	new[180]|new[181]	_	_
19-5	3880-3884	left	abstract[180]|place[181]	new[180]|new[181]	_	_
19-6	3885-3897	dorsolateral	abstract[180]|place[181]	new[180]|new[181]	_	_
19-7	3898-3908	prefrontal	abstract[180]|place[181]	new[180]|new[181]	_	_
19-8	3909-3915	cortex	abstract[180]|place[181]	new[180]|new[181]	_	_
19-9	3916-3922	yields	_	_	_	_
19-10	3923-3932	promising	abstract[182]	new[182]	_	_
19-11	3933-3940	results	abstract[182]	new[182]	_	_
19-12	3941-3942	.	_	_	_	_

#Text=Finally , Batalla et al. review the potential use of cannabidiol in addictive and comorbid psychotic disorders , pointing to a prominent role in the treatment of cannabis addiction .
20-1	3943-3950	Finally	_	_	_	_
20-2	3951-3952	,	_	_	_	_
20-3	3953-3960	Batalla	_	_	_	_
20-4	3961-3963	et	_	_	_	_
20-5	3964-3967	al.	_	_	_	_
20-6	3968-3974	review	_	_	_	_
20-7	3975-3978	the	abstract[183]	new[183]	_	_
20-8	3979-3988	potential	abstract[183]	new[183]	_	_
20-9	3989-3992	use	abstract[183]	new[183]	_	_
20-10	3993-3995	of	abstract[183]	new[183]	_	_
20-11	3996-4007	cannabidiol	abstract[183]|substance[184]	new[183]|new[184]	_	_
20-12	4008-4010	in	abstract[183]|substance[184]	new[183]|new[184]	_	_
20-13	4011-4020	addictive	abstract[183]|substance[184]|abstract[185]	new[183]|new[184]|giv[185]	_	_
20-14	4021-4024	and	abstract[183]|substance[184]|abstract[185]	new[183]|new[184]|giv[185]	_	_
20-15	4025-4033	comorbid	abstract[183]|substance[184]|abstract[185]	new[183]|new[184]|giv[185]	_	_
20-16	4034-4043	psychotic	abstract[183]|substance[184]|abstract[185]	new[183]|new[184]|giv[185]	_	_
20-17	4044-4053	disorders	abstract[183]|substance[184]|abstract[185]	new[183]|new[184]|giv[185]	_	_
20-18	4054-4055	,	_	_	_	_
20-19	4056-4064	pointing	_	_	_	_
20-20	4065-4067	to	_	_	_	_
20-21	4068-4069	a	abstract[186]	new[186]	_	_
20-22	4070-4079	prominent	abstract[186]	new[186]	_	_
20-23	4080-4084	role	abstract[186]	new[186]	_	_
20-24	4085-4087	in	abstract[186]	new[186]	_	_
20-25	4088-4091	the	abstract[186]|abstract[187]	new[186]|new[187]	_	_
20-26	4092-4101	treatment	abstract[186]|abstract[187]	new[186]|new[187]	_	_
20-27	4102-4104	of	abstract[186]|abstract[187]	new[186]|new[187]	_	_
20-28	4105-4113	cannabis	abstract[186]|abstract[187]|substance|event[189]	new[186]|new[187]|giv|giv[189]	_	_
20-29	4114-4123	addiction	abstract[186]|abstract[187]|event[189]	new[186]|new[187]|giv[189]	_	_
20-30	4124-4125	.	_	_	_	_

#Text=Scientific advances and new technologies are providing new tools that let us expand our knowledge , and improve diagnosis and treatment of addictive behaviors , presenting us with opportunity for success and giving people back their health .
21-1	4126-4136	Scientific	abstract[190]	giv[190]	_	_
21-2	4137-4145	advances	abstract[190]	giv[190]	_	_
21-3	4146-4149	and	abstract[190]	giv[190]	_	_
21-4	4150-4153	new	abstract[190]|abstract[191]	giv[190]|giv[191]	_	_
21-5	4154-4166	technologies	abstract[190]|abstract[191]	giv[190]|giv[191]	_	_
21-6	4167-4170	are	_	_	_	_
21-7	4171-4180	providing	_	_	_	_
21-8	4181-4184	new	abstract[192]	giv[192]	_	_
21-9	4185-4190	tools	abstract[192]	giv[192]	_	_
21-10	4191-4195	that	_	_	_	_
21-11	4196-4199	let	_	_	_	_
21-12	4200-4202	us	person	giv	ana	21-14
21-13	4203-4209	expand	_	_	_	_
21-14	4210-4213	our	person|abstract[195]	giv|giv[195]	ana	21-27
21-15	4214-4223	knowledge	abstract[195]	giv[195]	_	_
21-16	4224-4225	,	_	_	_	_
21-17	4226-4229	and	_	_	_	_
21-18	4230-4237	improve	_	_	_	_
21-19	4238-4247	diagnosis	abstract	giv	_	_
21-20	4248-4251	and	_	_	_	_
21-21	4252-4261	treatment	abstract[197]	new[197]	_	_
21-22	4262-4264	of	abstract[197]	new[197]	_	_
21-23	4265-4274	addictive	abstract[197]|abstract[198]	new[197]|new[198]	_	_
21-24	4275-4284	behaviors	abstract[197]|abstract[198]	new[197]|new[198]	_	_
21-25	4285-4286	,	_	_	_	_
21-26	4287-4297	presenting	_	_	_	_
21-27	4298-4300	us	person	giv	_	_
21-28	4301-4305	with	_	_	_	_
21-29	4306-4317	opportunity	abstract[200]	new[200]	_	_
21-30	4318-4321	for	abstract[200]	new[200]	_	_
21-31	4322-4329	success	abstract[200]|abstract	new[200]|new	_	_
21-32	4330-4333	and	_	_	_	_
21-33	4334-4340	giving	_	_	_	_
21-34	4341-4347	people	person	new	ana	21-36
21-35	4348-4352	back	_	_	_	_
21-36	4353-4358	their	person|abstract[204]	giv|giv[204]	_	_
21-37	4359-4365	health	abstract[204]	giv[204]	_	_
21-38	4366-4367	.	_	_	_	_
